Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Amgen returns epratuzumab rights to Immunomedics

April 15, 2004

Financing at Favrille supports phase II and phase III trials

April 14, 2004

ZymoGenetics cleared to commence phase I study of IL-21

April 7, 2004

Improvement in survival indicated in phase IIb trial of L-BLP-25

April 7, 2004

Promising initial clinical results for HYB-2055 presented in Orlando

April 6, 2004

AMD-3100 enters fifth phase II trial for stem cell transplantation

April 6, 2004

Canvaxin reported to improve survival of patients with early stage melanoma

April 6, 2004

Immunotherapy with antigen presenting cells for metastatic breast and prostate cancer

April 6, 2004

Monoclonal antibody effective against cancer progression in vivo

April 5, 2004

WX-G250 plus IFNalpha-2a reported safe and effective in renal cell carcinoma

April 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...